IMRT Tomotherapy for Esophagus Cancer (IMRT)
IMRT Tomotherapy for Esophagus Cancer: A Phase I Feasibility Study in Non-Operative Patients
研究概览
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Missouri
-
St. Louis、Missouri、美国、63110
- Washington University School of Medicine
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age >= 18
- Karnofsky Performance Status of >= 60
- TNM Stages T1-4, N0-3, M0
- Pathologic confirmation of esophagus cancer
- Evaluation by medical oncologist determines that the patient is medically fit for concurrent chemotherapy
- Evaluation by surgeon determines that patient is unresectable
Exclusion Criteria:
- Age < 18
- Karnofsky Performance Status < 60
- Radiographic or pathologic evidence of distant metastatic disease (classified as M1b in AJCC staging manual)
- Prior radiation therapy to the thorax or upper abdomen, preventing definitive radiation therapy.
- Pregnant or lactating, if female.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:IMRT + Concurrent chemotherapy
180 cGy daily fractions to a total dose of 5400 cGy to PTV1 and 200 cGy daily fractions to a total dose of 6000 cGy to PTV2. Once a day, five days a week, for approximately 6 weeks. Planned chemotherapy: cisplatin (75 mg/m2) day 1 and 5-FU (1000 mg/m2) days 1-4 on weeks 1, 5, 10, and 14 of therapy. Please note that drug regimens and doses may vary and will be at the discretion of the medical oncologist. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
The study will evaluate the feasibility of using helical tomotherapy to deliver IMRT in patients with unresectable esophagus cancer.
大体时间:One year after protocol registration
|
The study will be deemed infeasible if one or more of the following results occur:
|
One year after protocol registration
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Evaluate local recurrence rates
大体时间:Until patient progressive disease or death
|
6 weeks after therapy, every 3 months for first two years post therapy, every 6 months for years 3, 4, and 5 post therapy, and then annually.
|
Until patient progressive disease or death
|
Evaluate disease-free survival rates
大体时间:Until patient progressive disease or death
|
6 weeks after therapy, every 3 months for first two years post therapy, every 6 months for years 3, 4, and 5 post therapy, and then annually.
|
Until patient progressive disease or death
|
Evaluate regional recurrence rates
大体时间:Until patient progressive disease or death
|
6 weeks after therapy, every 3 months for first two years post therapy, every 6 months for years 3, 4, and 5 post therapy, and then annually.
|
Until patient progressive disease or death
|
Evaluate distant recurrence rates
大体时间:Until patient progressive disease or death
|
6 weeks after therapy, every 3 months for first two years post therapy, every 6 months for years 3, 4, and 5 post therapy, and then annually.
|
Until patient progressive disease or death
|
Evaluate overall survival rates
大体时间:Until patient progressive disease or death
|
6 weeks after therapy, every 3 months for first two years post therapy, every 6 months for years 3, 4, and 5 post therapy, and then annually.
|
Until patient progressive disease or death
|
合作者和调查者
调查人员
- 首席研究员:Jeffrey Bradley, MD、Washington University School of Medicine
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
调强放射治疗的临床试验
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG Oncology完全的
-
University College, LondonCancer Research UK; NCRI Radiotherapy Trials QA (RTTQA) Group完全的